<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02805881</url>
  </required_header>
  <id_info>
    <org_study_id>NRLF-BY531-CTIL</org_study_id>
    <nct_id>NCT02805881</nct_id>
  </id_info>
  <brief_title>Safety and Feasibility of Combined Trigeminal and Occipital Transcutaneous Nerve Stimulation (CTO-TNS) in Major Depressive Disorder (MDD)</brief_title>
  <acronym>CTO-TNS</acronym>
  <official_title>Safety and Feasibility of Combined Trigeminal and Occipital Transcutaneous Nerve Stimulation (CTO-TNS) in Major Depressive Disorder (MDD)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Neurolief Ltd.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Neurolief Ltd.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Safety and Feasibility of Combined Trigeminal and Occipital Transcutaneous Nerve Stimulation&#xD;
      (CTO-TNS) in Major Depressive Disorder (MDD)&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>May 2016</start_date>
  <completion_date type="Actual">July 2021</completion_date>
  <primary_completion_date type="Actual">July 2021</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Incidence of Treatment-Emergent Adverse Events</measure>
    <time_frame>6 weeks</time_frame>
    <description>Safety measures will be recorded and evaluated at every evaluation visit. It will be coded using the Medical Dictionary for Regulatory Activities. Vital signs (blood pressure and pulse) will be assessed and documented at each evaluation visit.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Hamilton Depression Rating Scale (HDRS21)</measure>
    <time_frame>6 weeks</time_frame>
    <description>Change in the total score on the Hamilton Depression Rating Scale (HDRS21) from baseline (visit 1) to week 6 (visit 4).</description>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">28</enrollment>
  <condition>Major Depressive Disorder</condition>
  <arm_group>
    <arm_group_label>Neurolief System treatment</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Treatment with the Neurolief system will be applied by the subject at his home and/or surrounding daily during a period of six weeks</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Neurolief system</intervention_name>
    <description>Non-invasive cephalic neurostimulation device</description>
    <arm_group_label>Neurolief System treatment</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  The subject is capable of understanding the study and to sign an informed consent.&#xD;
&#xD;
          -  Subject is between the ages of 18 to 65 years old.&#xD;
&#xD;
          -  Unipolar major depressive disorder&#xD;
&#xD;
          -  Score on the Hamilton Depression Rating Scale (HDRS21) &gt; 22&#xD;
&#xD;
          -  Current MDD episode &gt;3 months&#xD;
&#xD;
          -  Nonresponse with &gt;6 week use of one to six antidepressant in current episode&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  History of neurosurgical interventions.&#xD;
&#xD;
          -  Subjects with metal implants or shrapnel in their head, except for dental implants.&#xD;
&#xD;
          -  Skin lesion or inflammation at the region of the stimulating electrodes.&#xD;
&#xD;
          -  Pregnancy or Lactation.&#xD;
&#xD;
          -  Women of reproductive age not using efficient contraceptive method.&#xD;
&#xD;
          -  History of cerebrovascular event.&#xD;
&#xD;
          -  Psychotic or bipolar depression&#xD;
&#xD;
          -  History of schizophrenia, schizoaffective disorder or other non-mood disorder&#xD;
             psychosis&#xD;
&#xD;
          -  Current delirium, dementia, amnestic disorder or other cognitive disorders&#xD;
&#xD;
          -  Clinically significant current suicidal intent as assessed by the investigator team.&#xD;
&#xD;
          -  Obsessive-compulsive disorder or post-traumatic stress disorder&#xD;
&#xD;
          -  Alcohol and non-alcohol psychoactive substance abuse or dependence&#xD;
&#xD;
          -  Significant cardiac, medical, or progressive neurological or medical illness&#xD;
&#xD;
          -  An implantable electrical device such as a pacemaker.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Hilik Levkovitz, Prof.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Deputy Director, Beer- Yakov Nees-Ziona Mental Health Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Beer- Yakov Nees-Ziona Mental Health Center</name>
      <address>
        <city>Ness Ziona</city>
        <country>Israel</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Israel</country>
  </location_countries>
  <verification_date>August 2021</verification_date>
  <study_first_submitted>June 7, 2016</study_first_submitted>
  <study_first_submitted_qc>June 15, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 20, 2016</study_first_posted>
  <last_update_submitted>August 30, 2021</last_update_submitted>
  <last_update_submitted_qc>August 30, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">September 5, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Depressive Disorder</mesh_term>
    <mesh_term>Depression</mesh_term>
    <mesh_term>Depressive Disorder, Major</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

